Psychiatric Times

07/25/2025

What cascade of factors can lead to a "difficult" or treatment-resistant patient? Integrating psychodynamic skills with biomedical approaches can improve outcomes for these patients. https://www.psychiatrictimes.com/view/psychodynamic-therapy-and-the-difficult-patient

07/24/2025

Need CME Credit? Learn more about best practices in prescribing monoamine oxidase inhibitors for the treatment of major depressive disorder in this month's CME article!

In this CME article, discover effective strategies for prescribing MAOIs in treating major depressive disorder.

07/23/2025

According to new positive topline from a phase 3 trial, participants treated with AD109, the first oral pill for obstructive sleep apnea, saw clinically meaningful and statistically significant reductions in airway obstruction at 26 weeks with sustained efficacy at week 51. https://www.psychiatrictimes.com/view/positive-topline-results-from-phase-3-trial-of-ad109-first-oral-pill-for-obstructive-sleep-apnea

07/21/2025

New positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

07/21/2025

BioXcel Therapeutics has submitted a pre-supplemental New Drug Application meeting package to the FDA for Igalmi in support of a potential label expansion for outpatient use for the acute treatment of agitation associated with bipolar disorders or schizophrenia.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

07/18/2025

The FDA Advisory Committee has voted against recommending brexpiprazole plus sertraline for PTSD.

The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.

07/18/2025

The FDA advisory committee is currently meeting to discuss the sNDA for brexpiprazole (Rexulti) tablets in combination with sertraline for the treatment of adults with PTSD. Keep your eyes here and on the "Drug Watch" section of Psychiatric Times for all the latest updates: https://www.psychiatrictimes.com/topics/drug-watch

07/17/2025

There is no one-size-fits all approach to treating Major Depressive Disorder ( ). In this Expert Perspectives video, Leslie Citrome, MD, delves into the complexities of MDD and approaches to treating this disorder. He’ll also explore Treatment-Emergent Sexual Dysfunction (TESD) in MDD patients, emphasizing the importance of ongoing conversations with patients to ensure their treatment aligns with their needs. Watch now for key clinical insights. https://hubs.li/Q03tzc750

PAID CONTENT FROM TAKEDA PHARMACEUTICALS.

07/17/2025

Seaport Therapeutics just announced that the first patient has been dosed in the phase 2b BUOY-1 study of GlyphAllo in major depressive disorder with or without anxious distress. If successful, GlyphAllo could be a first-in-class treatment. https://www.psychiatrictimes.com/view/first-patient-dosed-in-phase-2b-study-of-glyphallo-for-patients-with-major-depressive-disorder-with-or-without-anxious-stress

07/14/2025

Serum drug levels offer essential insights into medication efficacy and patient responsiveness. Learn more in this month's editorial. https://www.psychiatrictimes.com/view/using-serum-drug-levels

07/10/2025

The FDA has granted Breakthrough Therapy designation to Transcend Therapeutics for their compound TSND-201 (methylone) for the treatment of PTSD. https://www.psychiatrictimes.com/view/tsnd-201-receives-breakthrough-therapy-designation-from-fda-for-ptsd

07/08/2025

Johnson & Johnson has submitted an sNDA to the FDA based upon long-term data evaluating the safety and efficacy of lumateperone (Caplyta) for the prevention of relapse in schizophrenia.

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.